InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing
Proceeds to Support Ongoing Clinical Development of InRhythm™, A First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation (PAF) Positive Phase 2 Data Scheduled for Presentation at American Heart Association Scientific Sessions 2020; Pivotal Phase 3 Study Planned for Initiation in H1 2021 SAN FRANCISCO, Oct. 21,...